Table 2.
Authors | Year | Study design | Study design total incidence of AO | |||||
---|---|---|---|---|---|---|---|---|
OCP users, females | Non-OCP user, male and females | Non-OCP users, females | ||||||
n | (%) | n | (%) | n | (%) | |||
Lilly et al., [12] | 1974 | Prospective | 192 | 21.4 | 975 | 7.9 | 489 | 7.2 |
Schow et al., [13] | 1974 | Prospective | 168 | 44.6 | 912 | 17.0 | 288 | 20.5 |
Butler et al., [14] | 1977 | Prospective | 36 | 19.4 | — | — | 174 | 5.7 |
Nordenram et al., [15] | 1983 | Prospective | 78 | 12.8 | — | — | 78 | 23.1 |
Al-Khateeb et al., [16] | 1991 | Prospective | 17 | 23.5 | 395 | 17.5 | 112 | 16.1 |
Larsen et al., [17] | 1992 | Prospective | 16 | 18.8 | 86 | 18.6 | 36 | 25.0 |
Bonine et al., [18] | 1995 | Prospective | 47 | 27.7 | 607 | 11.2 | 357 | 12.3 |
Hermesch et al., [7] | 1998 | Clinical trial | 59 | 35.6 | 212 | 20.8 | 111 | 21.6 |
Garcia et al., [19] | 2003 | Prospective | 87 | 11.5 | — | — | 180 | 3.9 |
Blondeau et al., [20] | 2007 | Prospective | 111 | 9.0 | 305 | 3.3 | 80 | 7.5 |
Alwraikat et al., [21] | 2009 | Prospective | 245 | 15.9 | 842 | 11.8 | 341 | 14.4 |
Sivolella et al., [22] | 2010 | Prospective | 38 | 2.6 | — | — | 80 | 1.3 |
Eshghpour et al., [23] | 2013 | Cross-sectional | 66 | 24.2 | 190 | 17.9 | 52 | 11.5 |
Eshghpour et al., [24] | 2013 | Clinical trial | 132 | 29.5 | — | — | 158 | 22.5 |
Almeida et al., [25] | 2016 | Retrospective | 29 | 37.9 | 334 | 11.7 | 179 | 8.9 |
Bhujbal et al., [26] | 2019 | Prospective | 194 | 16.0 | 793 | 3.8 | 307 | 3.9 |
Nilesh et al., [27] | 2019 | Prospective | 42 | 16.3 | 618 | 7.1 | 166 | 6.9 |